These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24386929)

  • 1. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection.
    Erbes T; Orlowska-Volk M; Zur Hausen A; Rücker G; Mayer S; Voigt M; Farthmann J; Iborra S; Hirschfeld M; Meyer PT; Gitsch G; Stickeler E
    BMC Cancer; 2014 Jan; 14():4. PubMed ID: 24386929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
    Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
    Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
    Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
    Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.
    Hessler LK; Molitoris JK; Rosenblatt PY; Bellavance EC; Nichols EM; Tkaczuk KHR; Feigenberg SJ; Bentzen SM; Kesmodel SB
    Ann Surg Oncol; 2017 Oct; 24(10):2907-2914. PubMed ID: 28766198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice.
    Lee SB; Yu JH; Park H; Kim HJ; Park SH; Chae BJ; Youn HJ; Jung SY; Kim EK; Jung YS; Son BH
    Asian J Surg; 2019 Jan; 42(1):314-319. PubMed ID: 30049563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance of intraoperative frozen section analysis with definitive histology of sentinel lymph nodes in breast cancer surgery: complementary axillary lymph node dissection is irrelevant for subsequent systemic therapy.
    Geertsema D; Gobardhan PD; Madsen EV; Albregts M; van Gorp J; de Hooge P; van Dalen T
    Ann Surg Oncol; 2010 Oct; 17(10):2690-5. PubMed ID: 20422461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
    Kilbride KE; Lee MC; Nees AV; Cimmino VM; Diehl KM; Sabel MS; Hayes DF; Schott AF; Kleer CG; Chang AE; Newman LA
    Ann Surg Oncol; 2008 Nov; 15(11):3252-8. PubMed ID: 18784961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.
    Grossmith S; Nguyen A; Hu J; Plichta JK; Nakhlis F; Cutone L; Dominici L; Golshan M; Duggan M; Carter K; Rhei E; Barbie T; Calvillo K; Nimbkar S; Bellon J; Wong J; Punglia R; Barry W; King TA
    Ann Surg Oncol; 2018 Nov; 25(12):3527-3534. PubMed ID: 29868979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes.
    Plecha D; Bai S; Patterson H; Thompson C; Shenk R
    Ann Surg Oncol; 2015 Dec; 22(13):4241-6. PubMed ID: 25814365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.
    Zetterlund L; Celebioglu F; Hatschek T; Frisell J; de Boniface J
    Br J Surg; 2021 May; 108(5):583-589. PubMed ID: 34043772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.